Quoin Pharmaceuticals
QNRX | NASDAQ
$3.56
-$0.14 (-3.78%)
At close: Nov 16, 2026, 4:00 PM ET
$3.69
+$0.13 (+3.65%)
After-hours:
Nov 16, 2026, 4:10 PM ET
Quoin Pharmaceuticals Company Profile
Company profile explainedCompany Profile
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.
Key Executives
| Name | Position |
|---|---|
| Michael Myers | Co-Founder, Chief Executive Officer & Chairman |
| Denise Carter | Co-Founder, Chief Operating Officer & Director |
| Sally Lawlor | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 28, 2026 | S-3 | Filing |
| Oct 26, 2026 | 4/A | [Amend] Filing |
| Oct 20, 2026 | 8-K | Current Report |
| Oct 14, 2026 | 8-K | Current Report |
| Oct 07, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 02, 2026 | DEF 14A | Filing |
| Sep 25, 2026 | EFFECT | Filing |
| Sep 25, 2026 | 424B3 | Filing |
| Sep 22, 2026 | PRE 14A | Filing |
| Sep 22, 2026 | 8-K | Current Report |
Quoin Pharmaceuticals
| Country | United States |
| IPO Date | Aug 1, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Michael Myers |
Contact Details
42127 Pleasant Forest Court Ashburn,
Virginia 20148-7349 United States
Stock Details
| Ticker Symbol | QNRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001671502 |
| CUSIP Number | 74907L409 |
| ISIN Number | US74907L4095 |
| SIC Code | 3841 |
Add to Watchlist
Select watchlists to add or remove QNRX